FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282921745> ?p ?o ?g. }

• W4282921745 endingPage "1325" @default.
• W4282921745 startingPage "1318" @default.
• W4282921745 abstract "Abstract HER2 is expressed in many pediatric solid tumors and is a target for innovative immune therapies including CAR-T cells and antibody–drug conjugates (ADC). We evaluated the preclinical efficacy of trastuzumab deruxtecan (T-DXd, DS-8201a), a humanized monoclonal HER2-targeting antibody conjugated to a topoisomerase 1 inhibitor, DXd, in patient- and cell line–derived xenograft (PDX/CDX) models. HER2 mRNA expression was determined using RNA-seq and protein expression via IHC across multiple pediatric tumor PDX models. Osteosarcoma (OS), malignant rhabdoid tumor (MRT), and Wilms tumor (WT) models with varying HER2 expression were tested using 10 mice per group. Additional histologies such as Ewing sarcoma (EWS), rhabdomyosarcoma (RMS), neuroblastoma (NB), and brain tumors were evaluated using single mouse testing (SMT) experiments. T-DXd or vehicle control was administered intravenously to mice harboring established flank tumors at a dose of 5 mg/kg on day 1. Event-free survival (EFS) and objective response were compared between treatment and control groups. HER2 mRNA expression was observed across histologies, with the highest expression in WT (median = 22 FPKM), followed by MRT, OS, and EWS. The relationship between HER2 protein and mRNA expression was inconsistent. T-DXd significantly prolonged EFS in 6/7 OS, 2/2 MRT, and 3/3 WT PDX models. Complete response (CR) or maintained CR (MCR) were observed for 4/5 WT and MRT models, whereas stable disease was the best response among OS models. SMT experiments also demonstrated activity across multiple solid tumors. Clinical trials assessing the efficacy of a HER2-directed ADC in pediatric patients with HER2-expressing tumors should be considered." @default.
• W4282921745 created "2022-06-16" @default.
• W4282921745 creator A5001852513 @default.
• W4282921745 creator A5009981843 @default.
• W4282921745 creator A5021615724 @default.
• W4282921745 creator A5029941351 @default.
• W4282921745 creator A5032743242 @default.
• W4282921745 creator A5040137655 @default.
• W4282921745 creator A5043927389 @default.
• W4282921745 creator A5044457816 @default.
• W4282921745 creator A5046943976 @default.
• W4282921745 creator A5056272469 @default.
• W4282921745 creator A5063003513 @default.
• W4282921745 creator A5068293265 @default.
• W4282921745 creator A5071747925 @default.
• W4282921745 creator A5073277560 @default.
• W4282921745 creator A5078531443 @default.
• W4282921745 creator A5080703966 @default.
• W4282921745 creator A5090752952 @default.
• W4282921745 date "2022-06-02" @default.
• W4282921745 modified "2023-10-17" @default.
• W4282921745 title "Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium" @default.
• W4282921745 cites W1571073982 @default.
• W4282921745 cites W1906032860 @default.
• W4282921745 cites W1966823692 @default.
• W4282921745 cites W1967464452 @default.
• W4282921745 cites W1973033337 @default.
• W4282921745 cites W1982093899 @default.
• W4282921745 cites W1998310148 @default.
• W4282921745 cites W2001627828 @default.
• W4282921745 cites W2027863358 @default.
• W4282921745 cites W2073323418 @default.
• W4282921745 cites W2086478541 @default.
• W4282921745 cites W2086604035 @default.
• W4282921745 cites W2122608679 @default.
• W4282921745 cites W2138604360 @default.
• W4282921745 cites W2157003991 @default.
• W4282921745 cites W2159363679 @default.
• W4282921745 cites W2492058432 @default.
• W4282921745 cites W2514294016 @default.
• W4282921745 cites W2737870005 @default.
• W4282921745 cites W2760931533 @default.
• W4282921745 cites W2906851106 @default.
• W4282921745 cites W2986723641 @default.
• W4282921745 cites W2996630100 @default.
• W4282921745 cites W3000389195 @default.
• W4282921745 cites W3005585857 @default.
• W4282921745 cites W3016619323 @default.
• W4282921745 cites W3110828287 @default.
• W4282921745 cites W3129393016 @default.
• W4282921745 cites W3138977263 @default.
• W4282921745 cites W3147820834 @default.
• W4282921745 cites W3159805754 @default.
• W4282921745 doi "https://doi.org/10.1158/1535-7163.mct-21-0758" @default.
• W4282921745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35657346" @default.
• W4282921745 hasPublicationYear "2022" @default.
• W4282921745 type Work @default.
• W4282921745 citedByCount "4" @default.
• W4282921745 countsByYear W42829217452022 @default.
• W4282921745 countsByYear W42829217452023 @default.
• W4282921745 crossrefType "journal-article" @default.
• W4282921745 hasAuthorship W4282921745A5001852513 @default.
• W4282921745 hasAuthorship W4282921745A5009981843 @default.
• W4282921745 hasAuthorship W4282921745A5021615724 @default.
• W4282921745 hasAuthorship W4282921745A5029941351 @default.
• W4282921745 hasAuthorship W4282921745A5032743242 @default.
• W4282921745 hasAuthorship W4282921745A5040137655 @default.
• W4282921745 hasAuthorship W4282921745A5043927389 @default.
• W4282921745 hasAuthorship W4282921745A5044457816 @default.
• W4282921745 hasAuthorship W4282921745A5046943976 @default.
• W4282921745 hasAuthorship W4282921745A5056272469 @default.
• W4282921745 hasAuthorship W4282921745A5063003513 @default.
• W4282921745 hasAuthorship W4282921745A5068293265 @default.
• W4282921745 hasAuthorship W4282921745A5071747925 @default.
• W4282921745 hasAuthorship W4282921745A5073277560 @default.
• W4282921745 hasAuthorship W4282921745A5078531443 @default.
• W4282921745 hasAuthorship W4282921745A5080703966 @default.
• W4282921745 hasAuthorship W4282921745A5090752952 @default.
• W4282921745 hasConcept C121608353 @default.
• W4282921745 hasConcept C126322002 @default.
• W4282921745 hasConcept C142724271 @default.
• W4282921745 hasConcept C159654299 @default.
• W4282921745 hasConcept C203014093 @default.
• W4282921745 hasConcept C2775999222 @default.
• W4282921745 hasConcept C2776715637 @default.
• W4282921745 hasConcept C2777325958 @default.
• W4282921745 hasConcept C2778256501 @default.
• W4282921745 hasConcept C2779786085 @default.
• W4282921745 hasConcept C2780844630 @default.
• W4282921745 hasConcept C2993561819 @default.
• W4282921745 hasConcept C502942594 @default.
• W4282921745 hasConcept C530470458 @default.
• W4282921745 hasConcept C542903549 @default.
• W4282921745 hasConcept C54355233 @default.
• W4282921745 hasConcept C71924100 @default.
• W4282921745 hasConcept C81885089 @default.
• W4282921745 hasConcept C86803240 @default.
• W4282921745 hasConceptScore W4282921745C121608353 @default.

• next